Lee, D.
Amadi, A.
Sabater, J.
Ellis, J.
Johnson, H.
Kotapati, S.
McNamara, S.
Walker, A.
Cooper, M.
Patterson, K.
Roskell, N.
Meng, Y.
Article History
First Online: 22 May 2018
Change Date: 11 September 2018
Change Type: Correction
Change Details: The second Key Point for Decision Makers, which reads:
Compliance with Ethical Standards
:
: Financial support for this study was provided entirely by a contract with Bristol-Myers Squibb Pharmaceuticals. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the report.
: DL, MC, KP, NR and YM are employees of BresMed, who have received consulting fees for the production of this manuscript from Bristol Myers Squibb. AW, HJ and SM have undertaken paid consultancy work for a number of pharmaceutical companies, including Bristol Myers Squibb. AA, JS, JE and SK are employees of Bristol Myers Squibb, the sponsoring pharmaceutical company. All affiliations were correct at the time of manuscript submission.
: The economic models used in this study are not publicly available in order to protect the commercial in confidence discounts that are in place for both nivolumab and ipilimumab.